Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00023660
Status:
COMPLETED
Last Update Posted:
2013-11-19
First Post:
2001-09-13
Brief Title:
Radiation Therapy Plus Celecoxib Fluorouracil and Cisplatin in Patients With Locally Advanced Cervical Cancer
Sponsor:
Radiation Therapy Oncology Group
Organization:
Radiation Therapy Oncology Group
Study Overview
Official Title:
A Phase III Study Of COX-2 Inhibitor CELEBREX CELECOXIB And Chemoradiation In Patients With Locally Advanced Cervical Cancer
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to damage tumor cells Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Giving radiation therapy in different ways and combining it with chemotherapy may kill more tumor cells Celecoxib may slow the growth of cervical cancer by stopping blood flow to the tumor
PURPOSE Phase III trial to study the effectiveness of radiation therapy plus celecoxib fluorouracil and cisplatin in treating patients who have locally advanced cervical cancer
PURPOSE Phase III trial to study the effectiveness of radiation therapy plus celecoxib fluorouracil and cisplatin in treating patients who have locally advanced cervical cancer
Detailed Description:
OBJECTIVES
Determine treatment-related toxicity rates in patients with locally advanced cervical cancer treated with external beam radiotherapy and brachytherapy concurrently with celecoxib fluorouracil and cisplatin
Determine whether this regimen increases locoregional control rates distant control disease-free survival and overall survival in these patients
Determine whether first-failure patterns in patients treated with this regimen are changed compared to historical controls
OUTLINE This is a multicenter study
Patients undergo external beam pelvic radiotherapy once daily five days a weeks for 5 weeks beginning on day 1 Within 8 weeks patients undergo low-dose or high-dose brachytherapy Patients also receive concurrent chemotherapy comprising fluorouracil IV continuously over days 2-5 23-26 and 44-47 and cisplatin IV over 4 hours on days 1 22 and 43 Oral celecoxib is administered twice daily beginning on day 1 and continuing for 12 months
Patients are followed every 3 months for 2 years every 4 months for 1 year every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 83 patients will be accrued for this study within 15 years
Determine treatment-related toxicity rates in patients with locally advanced cervical cancer treated with external beam radiotherapy and brachytherapy concurrently with celecoxib fluorouracil and cisplatin
Determine whether this regimen increases locoregional control rates distant control disease-free survival and overall survival in these patients
Determine whether first-failure patterns in patients treated with this regimen are changed compared to historical controls
OUTLINE This is a multicenter study
Patients undergo external beam pelvic radiotherapy once daily five days a weeks for 5 weeks beginning on day 1 Within 8 weeks patients undergo low-dose or high-dose brachytherapy Patients also receive concurrent chemotherapy comprising fluorouracil IV continuously over days 2-5 23-26 and 44-47 and cisplatin IV over 4 hours on days 1 22 and 43 Oral celecoxib is administered twice daily beginning on day 1 and continuing for 12 months
Patients are followed every 3 months for 2 years every 4 months for 1 year every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 83 patients will be accrued for this study within 15 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000068849 | None | None | None |